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Aim:  To  describe  the, incidence,  the  changes  in the  etiology  and  the prognosis  of  lower  respiratory  tract
infection  (LRTI)  in HIV infected  patients,  presenting  by  the  ﬁrst  time  to  the  Emergency  Department  (ED),
during  years  2000-2010.
Study design:  Prospective  collection  of data.
Metbods:  Data  were  collected  on  the  ﬁrst visit  of HIV-infected  patients  at our ED  due  to  a LRTI,  (deﬁned
according  to the criteria  of  the  European  Respiratory  Society),  between  1/1/2000  and  31/12/2010.  A series
of  epidemiological  and  laboratory  variables  as  well as  the  need  for admission  to the intensive  care  unit
(ICU).  LRTI  etiology  were  also  collected.  The  inﬂuence  ofthe  mentioned  variables  on  30-day  mortality
were  analyzed.
Results: One  hundred  thirty  one  patients  were included.  LRTI  represented  27%  of  visits  to  the  ED by
HIV-infected  patients.  Mean  age  was  39±9  years.  72%  of patients  were  males.  18% required  admission
to  the  ICU.  The  most  frequent  LRTI was  pneumonia  by  P. jiroveci  in 35  cases,  bacterial  penumonia  in  27
and  pulmonary  tuberculosis  in  20.  LRTI  incidence  gradually  reduced  signiﬁcantly  over time  from  6.13
×  1000 patients/year  in  year  2000  to 0.23 ×  1000  patients/year  in 2010 (p<0.05).  Overall  mortality  was
14%.  Logistic  regression  analysis  showed  that  admission  to ICU (p<0.004)  and viral  load  (p<0.029)  were
independent  variables  predicting  mortality.
Conclusion:  LRTI  is  a pathology  with  a decreasing  incidence,  probably  related  to the  widespread  utilization
increased  of HAART  regimens.  lts etiology  has  also  been  changing,  but  with  a non  negligible  mortality,
mostly  when  ICU admission  was  required.
© 2014  Elsevier  España,  S.L.U.  and  Sociedad  Española  de  Enfermedades  Infecciosas  y  Microbiología
Clínica.  All  rights  reserved.
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Objetivo:  Describir  la  incidencia,  la  etiología  y  el pronóstico  de la  infección  de  las  vías  respiratorias
bajas (IVRB)  en los  pacientes  VIH,  que  acudieron  a un  Servicio  de Urgencias  (SU), durante  el  período
del  2000–2010.
Disen˜o  del  estudio:  Estudio  prospectivo  de  10 an˜os  de  evolución.
Métodos:  Se recogió  únicamente  el primer  episodio  del paciente  que  acude  al  SU  por  IRVB (deﬁnida  según
la European  Respiratory  Society).  Se  analizaron  una  serie  de variables  epidemiológicas  y de  laboratorio,
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así  como  la  necesidad  de  ingreso  en  una  unidad  de cuidados  intensivos  (UCI).  Se  estudió  la  etiología  de  la
IRVB  y la  incidencia.  Finalmente  se  analizaron  la  inﬂuencia  de  las  variables  con  la  mortalidad  a  30  días.
Resultados:  Se  incluyeron  un  total  de  131  pacientes.  La  edad media  fue  de  39  ±  9  an˜os.  El  72% de los
pacientes  eran  varones  y  el 18%  de  los  pacientes  requirieron  ingreso  en  la UCI.  La  IRVB  más  frecuente  fue
la neumonía  por  P. jirovecci,  seguida  de  la  neumonía  bacteriana  en  27  y  la  tuberculosis  pulmonar  en  20.  La
incidencia  de  IRVB  se ha  ido reduciendo  gradualmente  de  forma  signiﬁcativa,  6,13  × 1.000  pacientes/an˜o
en 2000  a 0,23  ×  1.000  pacientes/an˜o  en  2010  (p  < 0,05).  El  análisis  de  regresión  logística  mostró  que  la
única variable  que  predijo  mortalidad  fue el  ingreso  en  UCI (p  <  0,05; OR:  73,01).
Conclusión:  La IRVB  es  una  enfermedad  cuya  incidencia  y  etiología  han  ido disminuyendo  y cambiando
respectivamente,  probablemente  en  relación  con  la  utilización  generalizada  del TAR.  Sin embargo,  todavía
presenta  una  mortalidad  nada  despreciable,  que es mayor  cuando  el paciente  requiere  ingreso  en  la UCI.
©  2014  Elsevier  España,  S.L.U.  y Sociedad  Española  de  Enfermedades  Infecciosas  y Microbiología  Clínica.
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The morbidity and mortality associated to infection by the
uman immunodeﬁciency virus (HIV)1 has dramatically decreased
ince highly active antiretroviral therapy (HAART) was ﬁrst
ntroduced in the mid-1990s. Respiratory pathology and, specif-
cally, acute lower respiratory tract infections (LRTI), have been
ne of the most frequent problems in HIV-infected patients with
 life-threatening prognosis in a large number of cases.2
In the pre-HAART era, the most common cause of community-
cquired pneumonia (CAP) was Pneumocystis jiroveci (PCP)
ccurring mainly in patients with <200 CD4/mm3 lymphocytes.3
fter the introduction of HAART and subsequent immune recov-
ry, the incidence of PCP has gone down but bacterial infections like
treptococcus pneumoniae have emerged as the ﬁrst cause of CAP.4
onversely, a reduction in the incidence of S. peumoniae invasive
isease (bacteremia) has been observed.5 Pulmonary tuberculosis
TBC) has always been a worldwide health problem with a great
mpact in the pre-HAART era, in HIV/AIDS population6–9 even in
he developed world. Nowadays, pulmonary tuberculosis develops
n HIV patients with relatively good immunological control and
ts incidence has become close to that of the immunocompetent
opulation of the same geographical area.
Emergency departments (ED) used to be the health resource that
IV patients utilize to receive acute medical care.10 In the setting
f antiretroviral therapy, most of ED consultations in HIV-infected
atients are due to reasons, not directly related with HIV infection.
he changing situation of HIV patients in the HAART era has led to
hanges in the reasons to seek emergency care along the years.11
owever, these changes may  not be well understood. We  have
een prospectively collecting data on ED admissions at Hospital
linic, a major hospital located in the center of Barcelona delivering
mergency care for a wide urban area.
We herewith describe the evolution of the incidence, etiology
nd prognosis of LRTI in HIV patients presenting for the ﬁrst time
o an ED, in the HAART era.
atients and methods
Prospective study (2000–2010), collecting data using a pre-
eﬁned form of the ﬁrst consultation to lower ED of patients
reviously diagnosed with HIV or newly diagnosed patients dur-
ng the patient’s admission to the ED that presented, with a LRTI.
atients diagnosed with LRTI derived from other hospitals were
xcluded. Patients diagnosed with LRTI transferred from other hos-
itals were excluded. LRTI was deﬁned according to the criteria
f the European Respiratory Society.12–14 AIDS criteria, includingPlease cite this article in press as: Perelló R, et al. Changes in the eti
infections in human immunodeﬁciency virus patients. Enferm Infecc M
neumonia by PCP and TB, were determined based on the 1993
DC15 recommendations. HAART was deﬁned as a combination
ntiretroviral therapy including at least three drugs. CAP was
eﬁned according to IDSA criteria.16,17Todos  los  derechos  reservados.
Mortality was considered related with the episode of LRTI if it
occurred within 30 days.
Our hospital is both a referral center and also a primary care
center, for an area of 500,000 inhabitants, 125,000 emergency visits
per year of, which 42,00018 in the area of medicine. Data collection
was carried out by reviewing the emergency department medical
records, which were subsequently compared with the database of
HIV patients followed up in our hospital on an outpatient basis
(at present about 5000 patients). The study was approved by the
Ethics Committee of our hospital and all patients participating in
the study signed an informed consent during their admission at the
ED. To calculate the incidence, HIV patients not controlled in our
hospital were excluded.
Blood cultures were performed using BACTEC 9240, Becton
Dickinson, NJ, EE.UU; good quality sputum samples, according to
Murray’s criteria,19 were gram stained and cultured. Urine anti-
gen for S. pneumoniae (Binax NOW S pneumoniae Urinary Antigen
Test) and L. Pneumophila (Binax NOW Legionella Urinary Antigen
Test) were also determined. When the patient presented with
radiological inﬁltrate and clinical symptoms compatible with TB,
Ziehl–Neelsen staining of the sputum, stools and gastric juice
were performed. Bronchoalveolar lavage (BAL) was  performed in
patients with respiratory insufﬁciency and radiological features
of suspected infection by PCP or Cytomegalovirus. If the patient
required mechanical ventilation a bronchoaspiration procedure
was performed. A nasopharyngeal smear from patients was  per-
formed to study respiratory viruses. It was processed for antigen
detection by indirect immunoﬂuorescence (IFI) (Chemicon interna-
cional Temula, California, EE.UU.), and for the detection of nucleic
acids was  performed by means of two  multiple and independent
reverse transcription nested polymerase chain reactions (RT-PCR).
When a fungal infection was  suspected, a fresh exam of the sputum
samples was  performed using Sabouraud’s agar culture or Giemsa
staining. The detection of AGA (anti transglutaminase antibodies)
in BAS or in BAL was determined by the sandwich-type immunoen-
zymatic assay in microplaques (“Platelia Aspergillus EIA” technique).
A series of epidemiological and laboratory variables such as
age, sex, HAART, cD4 lymphocyte count and viral load (VL) were
assessed prior to admission. In addition, meeting AIDS criteria, the
patient’s need for admission to the intensive care unit (ICU) and
LRTI etiology were also assessed. Lastly, the inﬂuence of these vari-
ables on 30-day mortality in our hospital was analyzed. Patients
requiring admission to the ICU are those that meet at least one
of the following two criteria: vasoactive support or need for non-
invasive or invasive mechanical ventilation. The days of hospital
stay were collected but not ﬁnally included in the data analysis,
in order to reduce bias, since many patients had social pathology
and did not ﬁt the medical discharge with the actual discharge.ology, incidence and prognosis of acute lower respiratory track
icrobiol Clin. 2014. http://dx.doi.org/10.1016/j.eimc.2014.06.002
Categorical variables were expressed as frequencies and percent-
ages. All continuous variables were expressed as mean ± standard
deviation unless otherwise speciﬁed. Differences between groups
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ere evaluated using parametric tests if the variables were nor-
ally distributed and the non-parametric tests if the variables were
ot normally distributed. Proportions were compared with the Chi-
quare test and the Fisher’s exact test when necessary. Stepwise
ogistic regression analysis was performed to model the relation-
hip between mortality and each of the variables, including sex
nd age as potential confounders. A bilateral value of p < 0.05 was
onsidered signiﬁcant. All statistical calculations were performed
sing the SPSS version 18.0 (Chicago, IL, USA).
esults
One hundred and thirty-one (27%) patients had a LRTI diagnosed
mong the 445 HIV infected patients with a ﬁrst visit to ED during
he 10 years study period. Mean age of these 131 patients was  39 ±
 years. 71% of the patients were males, 33% were receiving HAART,
1% met  AIDS criteria and 24 (18%) had to be admitted to the ICU,
ncluding 10 with mechanical invasive and 4 with noninvasive ven-
ilation (NIV). All patients admitted to the ICU, pointed vasoactive
rugs. Six patients required NIV but most were managed in the
D to the unavailability of ICU beds. The diagnosis of HIV infection
as done during the ED admission in 25 (19%) of these 131 patients.
he rest of epidemiological and laboratory variables are shown in
able 1.
The most frequent LRTI was pneumonia by PCP in 35 cases (27%),
ollowed by bacterial pneumonia in 27 cases (21%) and TB in 20
ases (15%). Five patients having being previously diagnosed with
hronic obstructive pulmonary disease were diagnosed with CAP.
acterial pneumonia was suspected in 66 cases but only microbio-
ogical isolation was obtained in 27. The most frequently identiﬁed
icroorganism was PCP in 35 cases, which was diagnosed by BAL in
3 (94%) patients, followed by induced sputum in 2 (6%) patients. In
ne patient with high suspicion of PCP pneumonia no microorgan-
sm could be identiﬁed. The most frequently diagnosed bacterium
as S. pneumoniae in 21 patients, 9 (43%) of which developed bac-
eriemia. Other bacteria identiﬁed were Sapht aureus,  H inﬂuenzae
nd Streptococcus viridans in 3, 2 and 1 patient, respectively. In 10
50%) patients with TBC, bacilloscopy was negative and the diag-
osis was established by pathological examination of the pleural
iopsy, the growth of mycobacterium in stool, urine or gastric
uice. In the remaining patients without microbiological diagnosis,
9 cases (37%), attending the clinical and radiological suspicion,
9 cases were treated as bacterial infection, 1 as PCP and 9 as TB.
o fungal or viral isolation was obtained in any patient.
The clinical course of the different LRTI pathologies is shown in
able 2.
The incidence of LRTI has decreased over time (p < 0.05), and
as dropped from initially being 6.13 × 1000 patients/year to being
.23 × 1000 patients/year in 2010 (Fig. 1).
The total mortality of the series was 14%, mainly due to PCP
n 50% of the cases. The variables that predicted a bad prog-
osis were the viral load (p < 0.007), absence of treatment with
AART (p < 0.040), and admission to the ICU (p < 0.001). Interest-
ngly though, after logistic regression analysis, the variables that
howed to be a predictor of death were admission to the ICU
p < 0.004) and the viral load (p < 0.029). Mortality from LRTI has
een decreasing during the last decade, from a 14.2% in the period
000–2004 to a 10% in the period 2005–2010 (data not shown). For
ll patients who died in our study, death took place at ICU.
iscussionPlease cite this article in press as: Perelló R, et al. Changes in the eti
infections in human immunodeﬁciency virus patients. Enferm Infecc M
In view of our results, LRTI accounts for 27% of the visits to
he ED in the HIV population and is one of the highest motives
or ED frequentation in the HIV population.20 These patients have
 non-negligible mortality that reaches 14%. Attending the globalpatients treated in our center who came to the ED. Denominator HIV patients in our
center assets per year.
cases, CAP continues to be nowadays the most frequent LRTI in
the HAART, with S. pneumoniae being the most common bacte-
rial etiology.21 Infections classically known as atypical, such as PCP
infection, that appear in patients that have a poor immunologi-
cal control (CD4 < 200 cells/mcL)3 are rapidly falling in HIV patients
receiving HAART, even though in our study, atypical infections con-
tinue to be the leading cause of mortality from LRTI. It is not always
possible to determine the immunological status of the patient at
the ED, and even more so, if the patient is not followed up in
the same hospital, which can give rise to diagnostic doubts on
whether the etiology of pneumonia may  or may  not be caused by
PCP. Because of this, Napoli et al.22 found that a total lymphocyte
value of <1700 cells/mm is a predisposing factor, but not the only
one to suffer an infection by PCP. Nowadays, LRTI by PCP is fre-
quently seen in non-HIV immunodepressed patients, such as those
with a transplanted solid organ, oncological patients and patients
that suffer from connective tissue diseases. This makes it necessary
to give this pathology more consideration and improve diagnos-
tic testing in order to start treatment against PCP in this type of
patients as early as possible.23,24 In our study we have seen that
the CAP and PCP had similar mortality knowing that they exhibit
different immune status, probably this result reinforces the study of
Bordon et al.25 which asserts that neither the levels of CD4 or viral
load is a factor of poor prognosis in HIV patient CAP hospitalized.
The management of CAP in patients with HIV infection should not
be based on CD4+ cell counts or HIV-RNA levels of the HIV infection.
TB was the third LRTI pathology accounting for 22% of the visits,
being more common in the HIV/AIDS population and in continents
such as Africa where it continues to have a high mortality.9 After
decades of decline, TB continues to be a worldwide health problem
in immunocompromised HIV patients. Microbiological diagnosis
is not always easy. Not even when the most modern techniques
are applied (such as the determination of the lipoarabinoman-
nan enzyme by the ELISA assay in induced sputum),26 it is always
possible to isolate mycobacterium. The standard tests to diagnose
mycobacterium tuberculosis are less sensitive when the patient has
low CD4 levels,27 which may, perhaps, explain the lack of microbi-
ological diagnosis of some patients in our series. Early diagnosis of
TB, as well as the use of HAART, improves prognosis, as its late onset
in patients with a previously conﬁrmed diagnosis of TB increases
mortality; which highlights the importance of good immunologi-
cal control in HIV patients.6,8 TB in Spain may be more commonology, incidence and prognosis of acute lower respiratory track
icrobiol Clin. 2014. http://dx.doi.org/10.1016/j.eimc.2014.06.002
in immigrants. In our study there were 2 patients from Pakistan
and one from Eastern Europe, although the only patient that died
was native. During the last 30 years pulmonary involvement has
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Table 1
Characteristics of the 131 study patients stratiﬁed by the etiology of the LRTI.
Total LRTI (n = 131) Bacterial infections
(n = 27)
Mycobacterial
infections (n = 20)
Pneumocystis
jiroveci (n = 35)
Unknown
ethiologya (n = 49)
Males 94 (71%)b 20 (74%) 15 (75%) 24 (68%) 35 (71%)
Age  (years) 39 ± 9c 37 ± 9 41 ± 11 41 ± 9 39 ± 9
Patients  with AIDS criteria 93 (71%)b 14 (51%) 16 (80%) 34 (97%) 93 (71%)
Viral  load (copy number/ml of plasma) 312.673 ± 5c 257.541 ± 3 599.493 ± 1 421.601 ± 3 312.673 ± 5
CD4+ lymphocytes/mm3 240 ± 274c 353 ± 298 226 ± 330 73 ± 91 240 ± 274
Patients on HAART 42 (32%)b 11 (40%) 5 (25%) 2 (5%) 24 (49%)
Mortality within 30 days 18 (13%)b 4 (14%) 1 (5%) 7 (20%) 6 (12%)
ICU  admission 24 (18%)b 8 (29%) 2 (10%) 9 (25%) 5 (10%)
LTRI, lower respiratory tract infections; HAART, highly active antiretroviral therapy; ICU, intensive care unit.
a Clinical diagnosis of LRTI but no microorganism identiﬁed.
b n (proportion).
c Mean ± SD.
Table 2
Predictors of mortality within 30 days.
Variables Mortality at 30 days Univariate analysis Multivariate analysis
Yes (n = 18) No (n = 113) Odds ratio 95% CI p value Odds ratio 95% CI p
Males 14 (77.8%)a 80 (70.8%) 0.69 0.21–2.26 0.779 1.130 0.088–16.394 0.929
Age  (years) 43 ± 11b 38 ± 9 0.958 0.913–1.006 0.082 0.971 0.887–1.062 0.516
Viral  load (copy Lumber/ml of plasma) 554.907 ± 3b 279.641 ± 5 1 1–1 0.007 1 1–1 0.029
CD4+ lymphocytes/mm3 167 ± 217b 249 ± 272 1.001 0.999–1.004 0.36 1.006 0.999–1.014 0.115
Patients on HAART 2 (11.1%)a 40 (35.4%) 0.228 0.050–1.043 0.055 1.549 0.077–31.203 0.775
Patients with AIDS criteria 15 (83%)a 78 (69%) 2.244 0.610–8.253 0.274 8.288 0.30–221.702 0.207
ICU  admission 15 (83%)a 9 (8%) 57.77 14.040–237.77 <0.001 1086 9.550–123701.13 0.004
Microbiological diagnosis
Mycobacteria 1 (5.6%) 19 (16.8%) 0.29 0.04–2.32 0.306 0.068 0.001–4.73 0.215
P.  Jirovencii 7 (38.9%) 28 (24.8%) 1.93 0.68–5.46 0.252 0.490 0.018–13.503 0.673
Bacterial Infection 4 (22.2%) 23 (20.4%) 1.12 0.33–3.72 1 – – –
Unknown 6 (33.3%) 43 (38.1%) 0.81 0.28–2.33 0.797 42.449 0.479–3765 0.101
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4. Danés C, González-Martín J, Pumarola T, Ran˜ó A, Benito N, Torres A, et al.talics values denote statistical signiﬁcance.
a n (proportion).
b Mean ± SD.
layed a major role in the history of HIV infection, being associ-
ted with greater impairment in self-reported physical function in
hese patients.28,29 With the introduction of HAART and subsequent
mmunological recovery of patients, pathology as cronical obstruc-
ive pulmonary diseases (COPD), a widely spread disease in the
eneral population, caused most signiﬁcantly by smoking,30 will
ncrease and will probably become a new and signiﬁcant comorbid-
ty for HIV patients, especially where there is airway colonization
y PCP.31 Hence, it would be advisable to conduct early diag-
osis screening of COPD in HIV patients with predisposing risk
actors,32 aimed at taking preventive measures. In a future health-
are providers should be aware of the increased likelihood of airway
bstruction among HIV patients.
Nowadays, as discussed above, HIV patients come to the ED
ore often due to pathologies that are not directly associated
ith HIV. This will continue to be the trend in patients with good
mmunological control, which, in turn, will entail longer hospital
tays and higher utilization of health resources,10,11,33 with the aim
f reducing their morbimortality and related healthcare costs.34
inally, our study shows a decrease in the incidence of LRTI and
ssociated mortality, even though it has not remained signiﬁcant
14%) in the last ten years. These improvements are owed probably
o HAART and to a wider range of antibiotics that were not available
efore. Our study has a series of limitations as it was conducted in
 single hospital, although our hospital is one of the most impor-
ant healthcare centers in Spain, not only in terms of number of HIV
atients in follow-up but also in terms of emergency visits volume.Please cite this article in press as: Perelló R, et al. Changes in the eti
infections in human immunodeﬁciency virus patients. Enferm Infecc M
espite this limitation, the sample is large enough to draw some
alid conclusions. The study of respiratory viruses was not carried
ut in its entirety. This is because the techniques that were avail-
ble in our hospital until the mid-2000s, such as virus cultures andindirect immunoﬂuorescence, provided low sensitivity in contrast
with currently available molecular biology techniques.35. Conse-
quently, viral pathology would have been underdiagnosed in the
referred period of study. The availability of a speciﬁc daycare center
in our hospital has made it possible to treat some uncomplicated
LRTI without to referral to the ED. In addition, patients referred
from other hospitals were excluded. Therefore, the incidence rates
reported may  be likely underestimating the real ones.
In summary our study, shows that LRTI is a condition in
HIV-infected patients seeking acute care showing a decreasing inci-
dence, a changing etiology to bacterial infections, and a trend to
decreasing mortality (not signiﬁcantly).
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